Leidos CEO Tom Bell emphasized the initiative's goal of improving healthcare access for underserved communities while training future healthcare specialists.

Anantha Shekhar, senior vice chancellor for the health sciences at the University of Pittsburgh, noted the collaboration's potential to enhance diagnosis, disease management, and overall healthcare delivery.

Joint research efforts will explore innovative imaging methods and advanced scanning technologies for analyzing tissue samples, fostering advancements in healthcare technology.

The University of Pittsburgh has a history of leveraging AI for diagnostic support and has previously partnered with NVIDIA to accelerate medical research efforts.

Surescripts has been designated as a Qualified Health Information Network (QHIN), enabling nationwide health data exchange under federal guidelines, which supports various healthcare entities in exchanging clinical information.

The University of Pittsburgh School of Medicine is recognized for its leadership in biomedical research, integrating technology with science to improve health outcomes.

Leidos has over 25 years of experience operating the National Cancer Institute’s Frederick National Laboratory and has applied AI in healthcare and other sectors for more than two decades.

The collaboration aims to develop AI-powered tools for faster detection of diseases such as heart disease and cancer, ultimately reducing diagnostic turnaround times and improving patient care.

University of Pittsburgh officials highlighted the partnership's potential to enhance healthcare delivery and innovation in diagnostics, positioning the institution as a leader in digital pathology.

This initiative seeks to merge academic excellence with technological innovation, redefining healthcare delivery and disease management for broader global impact.

In addition to technological advancements, the partnership will focus on workforce development by creating educational programs, including internships and annual symposiums, to cultivate future healthcare specialists and AI innovators.

Leidos has announced a substantial $10 million investment in a five-year partnership with the University of Pittsburgh's Computational Pathology and AI Center of Excellence (CPACE) to enhance AI applications for disease detection and management.